Previous 10 | Next 10 |
HOUSTON , March 12, 2020 /PRNewswire/ -- CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) ("CNS" or the "Company"), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers of the brain and central nervous system, today announced bu...
HOUSTON , Feb. 27, 2020 /PRNewswire/ -- CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) ("CNS" or the "Company"), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers of the brain and central nervous system, today announced the...
VANCOUVER, British Columbia, Feb. 12, 2020 (GLOBE NEWSWIRE) -- WPD Pharmaceuticals Inc. (CSE: WBIO)(FSE: 8SV1) (the “ Company ” or “ WPD ”), a clinical stage pharmaceutical company, is pleased to announce its plan to initiate a Phase I clinical trial for Berubici...
HOUSTON , Feb. 11, 2020 /PRNewswire/ -- CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) ("CNS" or the "Company"), a biotechnology company specializing in the development of novel treatments for brain tumors, today announced its plan to initiate a Phase I clinical trial for Berubicin in pedi...
HOUSTON , Feb. 4, 2020 /PRNewswire/ -- CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) ("CNS" or the "Company"), a biotechnology company specializing in the development of novel treatments for brain tumors, today announced it has completed the final GMP manufacturing run of its lead ca...
January 28, 2020 Palm Beach, FL – January 28, 2020 – Brain and other nervous system cancers are the 10th leading cause of death for men and women. The global G lioblastoma multiforme (GBM) drugs market to reach nearly $1.4 billion by 2025, expanding at a CAGR o...
HOUSTON , Jan. 28, 2020 /PRNewswire/ -- CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) ("CNS" or the "Company"), a biotechnology company specializing in the development of novel treatments for brain tumors, today announced that Anthem Biosciences of Bangalore, India (Anthem) has com...
January 14, 2020 Palm Beach, FL –January 14, 2020 – Targeted cancer therapies are drugs or substances which block the growth of cancer by interfering with molecules that are more specifically involved in cancer cell progression than in normal cell activity. The goal of t...
HOUSTON , Jan. 14, 2020 /PRNewswire/ -- CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) ("CNS" or the "Company"), a biotechnology company specializing in the development of novel treatments for brain tumors, today announced it has signed a contract with NCK A/S for the large scale prod...
January 13, 2020 Palm Beach, FL –January 13, 2020 – Reports say that the global drug delivery across brain barrier market size is expected to reach USD $4.6 billion by 2026, according to a new report by Grand View Research, Inc. registering a CAGR of 30.2% over the f...
News, Short Squeeze, Breakout and More Instantly...
CNS Pharmaceuticals Inc. Company Name:
CNSP Stock Symbol:
NASDAQ Market:
CNS Pharmaceuticals Inc. Website:
A look at the top 10 most actives in the United States Agape ATP Corporation (ATPC) rose 148.2% to $0.2172 on volume of 69,599,062 shares Imunon Inc. (IMNN) rose 154.6% to $3.03 on volume of 68,427,736 shares Jet.AI Inc. (JTAI) rose 27.2% to $0.380102 on volume of 41,454,602 shares SoFi T...
Strategic in-license from Cortice Bioscience is highly synergistic with the ongoing potentially pivotal Berubicin program and demonstrates further commitment to changing the treatment paradigm in GBM Drug candidate, TPI 287, awarded Orphan designation and studied in over 350 patients to date...
CNS Pharmaceuticals (NASDAQ: CNSP) , a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, will be participating in next month’s 2024 SNO/ASCO CNS Cancer Conference. The event will be held...